News
S&P, Nasdaq Close at New Record Highs, Ignore Weakness in LEI
Monday, July 21, 2025Markets were mixed in Monday trading today, closing at new all-timer highs on the S&P 500 and the Nasdaq, while dipping into the red on the blue-chip Dow index and the small-cap
RLI Corp. (RLI) Tops Q2 Earnings Estimates
RLI Corp. (RLI) came out with quarterly earnings of $0.84 per share, beating the Zacks Consensus Estimate of $0.75 per share. This compares to earnings of $0.86 per share a year ago. These figures
NXP Semiconductors (NXPI) Surpasses Q2 Earnings and Revenue Estimates
NXP Semiconductors (NXPI) came out with quarterly earnings of $2.72 per share, beating the Zacks Consensus Estimate of $2.66 per share. This compares to earnings of $3.2 per share a year ago. These
Medpace (MEDP) Q2 Earnings and Revenues Surpass Estimates
Medpace (MEDP) came out with quarterly earnings of $3.1 per share, beating the Zacks Consensus Estimate of $3 per share. This compares to earnings of $2.75 per share a year ago. These figures are
Alexandria Real Estate Equities (ARE) Tops Q2 FFO and Revenue Estimates
Alexandria Real Estate Equities (ARE) came out with quarterly funds from operations (FFO) of $2.33 per share, beating the Zacks Consensus Estimate of $2.29 per share. This compares to FFO of $2.36
W.R. Berkley (WRB) Tops Q2 Earnings and Revenue Estimates
W.R. Berkley (WRB) came out with quarterly earnings of $1.05 per share, beating the Zacks Consensus Estimate of $1.03 per share. This compares to earnings of $1.04 per share a year ago. These
Zions (ZION) Q2 Earnings and Revenues Surpass Estimates
Zions (ZION) came out with quarterly earnings of $1.58 per share, beating the Zacks Consensus Estimate of $1.31 per share. This compares to earnings of $1.21 per share a year ago. These figures are
BOK Financial (BOKF) Beats Q2 Earnings and Revenue Estimates
BOK Financial (BOKF) came out with quarterly earnings of $2.19 per share, beating the Zacks Consensus Estimate of $1.98 per share. This compares to earnings of $2.02 per share a year ago. These
Washington Trust Bancorp (WASH) Q2 Earnings and Revenues Top Estimates
Washington Trust Bancorp (WASH) came out with quarterly earnings of $0.68 per share, beating the Zacks Consensus Estimate of $0.63 per share. This compares to earnings of $0.63 per share a year ago
Crown Holdings (CCK) Surpasses Q2 Earnings and Revenue Estimates
Crown Holdings (CCK) came out with quarterly earnings of $2.15 per share, beating the Zacks Consensus Estimate of $1.86 per share. This compares to earnings of $1.81 per share a year ago. These
Agilysys (AGYS) Misses Q1 Earnings Estimates
Agilysys (AGYS) came out with quarterly earnings of $0.33 per share, missing the Zacks Consensus Estimate of $0.39 per share. This compares to earnings of $0.3 per share a year ago. These figures
AGNC Investment (AGNC) Q2 Earnings and Revenues Lag Estimates
AGNC Investment (AGNC) came out with quarterly earnings of $0.38 per share, missing the Zacks Consensus Estimate of $0.42 per share. This compares to earnings of $0.53 per share a year ago. These
Will Alphabet's Stock Keep Rebounding as Q2 Earnings Approach?
Following a tremulous start to the year, Alphabet GOOGL stock has helped lead the broader market’s historic rebound. Rebounding and soaring over +20% in the last three months, Alphabet stock is now
Domino’s Delivers Another Discounted Entry for Income Investors
Domino’s (NASDAQ DPZ) FQ2 results were weak, underperforming reduced expectations, with growth slowing and earnings in contraction, but that is not what investors should focus on. Those negative
ServisFirst Bancshares (SFBS) Q2 Earnings and Revenues Beat Estimates
ServisFirst Bancshares (SFBS) came out with quarterly earnings of $1.21 per share, beating the Zacks Consensus Estimate of $1.2 per share. This compares to earnings of $0.95 per share a year ago
Top Analyst Reports for Philip Morris, McDonald's & Texas Instruments
Monday, July 21, 2025The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Philip Morris
TSLA Earnings Week: Can Tesla Break Through $350?
Shares of Tesla Inc (NASDAQ: TSLA) have been rallying hard since April’s low, gaining more than 50% in that timeframe. A 3% pop last Friday added to the momentum, and the chart is showing signs
Goldman, Morgan Stanley, & BofA: Diverging Paths After Earnings
Wall Street just wrapped up a big week for earnings in the financial sector, and if there's one clear thing, it's that not all banks are built the same right now. With rising interest rates no
Build Stability and Income With 3 Overlooked Dividend Leaders
Dividend investing is one of the most popular strategies among retail investors seeking a combination of stability and passive income. A long-term buy-and-hold approach for stalwart dividend
Top Stock Picks for Week of July 21, 2025
Intuit Inc. (INTU) is a business and financial software company that develops and sells financial, accounting and tax preparation software and related services for small businesses, consumers and
3 Stocks Showcasing Strong Earnings Growth: NVDA, APP, GE
To assess earnings, examine the difference between revenues and production expenses. The growth of earnings is vital for every business, as survival depends on being profitable. Earnings are
The Ascent of Gold Stocks: Why Investors Can Buy Now
Gold continues to shine in 2025, outperforming the S&P 500 over the past 1-year, 3-year, and year-to-date periods. Amid dramatic geopolitical shifts, rising global uncertainty, and persistent
IBN's Q1 Earnings Rise Y/Y on Strong NII & Fee Income, Provisions Up
ICICI Bank Ltd.’s IBN net income for the first quarter of fiscal 2025 (ended June 30) was INR127.7 billion ($1.5 billion), up 15.5% from the prior-year quarter.
Results were driven by a rise in net
Ally Financial Q2 Earnings Miss on Lower Loans & Deposits
Ally Financial’s ALLY second-quarter 2025 adjusted earnings of 99 cents per share handily missed the Zacks Consensus Estimate of $1.01. However, the bottom line reflected a jump of 35.6% from the
Roche Stock: COPD Drug Failure Deals Pipeline Blow
Pharmaceutical giant Roche faces significant setbacks after its promising COPD drug candidate Astegolimab failed to meet primary endpoints in the crucial Phase III ARNASA study. The experimental
